BioCentury
ARTICLE | Company News

Kymriah becomes first CAR T available on NHS England

September 4, 2018 11:06 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said it has reached an agreement with NHS England to make Kymriah tisagenlecleucel available in England, which the agency said marks Europe's first full access deal for a CAR T therapy.

NHS access to Kymriah is limited to patients under 25 years old with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse...

BCIQ Company Profiles

Novartis AG

BCIQ Target Profiles

CD19